WeVote

Bill

Bill

SF 264

A bill for an act relating to prescription drug affordability, including the creation of a prescription drug affordability board.

2025-2026 Regular Session Introduced by Liz Bennett and 10 co-sponsors

Iowa SF 264 creates a prescription drug affordability board to monitor and address high medication costs through state-level oversight and potential pricing interventions.

Subcommittee: Klimesh, Celsi, and Costello.
0
WeVote Research Nonpartisan
Bill Summary · SF 264

Legislative bill overview

SF 264 proposes creating a prescription drug affordability board in Iowa to address high medication costs. The bill establishes a mechanism to monitor, analyze, and potentially regulate drug pricing within the state, though the specific regulatory powers and funding mechanisms are not detailed in the available information.

Why is this important

Prescription drug costs are a significant healthcare expense for Iowa residents, particularly seniors and uninsured populations. Creating an affordability board could help identify pricing disparities, negotiate better rates, or implement price controls—though implementation success depends heavily on the board's actual authority and resources, which are not yet specified in publicly available summaries.

Potential points of contention

  • Pharmaceutical industry opposition: Drug manufacturers may argue that price regulation undermines research and development investments, while supporters counter that current prices are unsustainably high
  • State vs. federal authority: Questions about whether Iowa can regulate drug prices without conflicting with federal pharmaceutical regulation and interstate commerce considerations
  • Board structure and power: Disagreement over whether the board should have advisory-only status, price-negotiation authority, or actual price-setting power, with cost implications for each approach

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.